Interim Financial Statements (Un-audited)

For the period July - December 2021

BEXIMCO PHARMA here's to life

Beximco Pharmaceuticals Limited

Beximco Pharmaceuticals Limited and its Subsidiaries

Financial Statements (Un-audited)

For the Period July - December 2021

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Financial Position (Un-audited)
As at December 31, 2021

Taka '000

	Notes	December 31, 2021	June 30, 2021
ASSETS			
Non-Current Assets		**47,688,160**	**38,475,238**
Property, Plant and Equipment- Carrying Value	5	41,855,972	36,211,376
Right-of-use Assets		496,567	319,885
Intangible Assets		4,561,931	1,380,694
Deferred Tax Asset		72,640	-
Goodwill	6	674,571	546,691
Other Investments	7	26,479	16,592
Current Assets		**17,391,901**	**13,770,846**
Inventories	8	9,351,456	7,142,863
Spares & Supplies		748,479	661,723
Accounts Receivable		3,584,766	2,873,845
Loans, Advances and Deposits	9	2,357,189	2,416,948
Advance Income Tax		169,310	-
Cash and Cash Equivalents	10	1,180,701	675,467
TOTAL ASSETS		**65,080,061**	**52,246,084**
SHAREHOLDERS' EQUITY AND LIABILITIES			
Equity Attributable to the Owners of the Company		**38,657,785**	**37,030,559**
Issued Share Capital		4,461,121	4,461,121
Share Premium		5,269,475	5,269,475
Excess of Issue Price over Face Value of GDRs		1,689,637	1,689,637
Capital Reserve on Merger		294,951	294,951
Revaluation Surplus		1,119,361	1,121,825
Unrealized Gain/(Loss)		23,654	13,767
Retained Earnings		25,799,586	24,179,783
Non-Controlling Interest		**4,138,350**	**334,307**
TOTAL EQUITY		**42,796,135**	**37,364,866**
Non-Current Liabilities		**9,062,106**	**5,531,540**
Long Term Borrowings-Net of Current Maturity	11 A	4,229,806	1,206,717
Liability for Gratuity and WPPF & Welfare Funds		2,848,816	2,335,257
Deferred Tax Liability		1,983,484	1,989,566
Current Liabilities and Provisions		**13,221,820**	**9,349,678**
Short Term Borrowings		4,745,994	5,023,181
Long Term Borrowings-Current Maturity	11 B	2,060,666	1,401,406
Creditors and Other Payables		3,382,666	1,965,048
Accrued Expenses		850,137	619,399
Dividend Payable / Unclaimed Dividend		1,615,164	118,138
Income Tax Payable		567,193	222,506
TOTAL EQUITY AND LIABILITIES		**65,080,061**	**52,246,084**

Osman Kaiser Chowdhury	**A B Siddiqur Rahman**	**Nazmul Hassan**	**Mohammad Ali Nawaz**	**Mohammad Asad Ullah, FCS**
Director	Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period July - December 2021

	Notes	July - December 2021	July - December 2020	October - December 2021	October - December 2020
		Taka '000			
Net Revenue		**16,968,904**	**14,400,189**	**8,499,583**	**7,474,259**
Cost of Goods Sold	12	(8,799,257)	(7,568,599)	(4,406,281)	(3,932,210)
Gross Profit		**8,169,647**	**6,831,590**	**4,093,302**	**3,542,049**
Operating Expenses		**(4,235,426)**	**(3,364,722)**	**(2,259,523)**	**(1,744,949)**
Administrative Expenses	13	(573,839)	(403,632)	(328,843)	(206,306)
Selling, Marketing and Distribution Expenses	14	(3,661,587)	(2,961,090)	(1,930,680)	(1,538,643)
Profit from Operations		**3,934,221**	**3,466,868**	**1,833,779**	**1,797,100**
Other Income	15	801,972	169,913	731,451	75,817
Finance Cost		(432,357)	(502,855)	(268,731)	(269,459)
Profit Before Contribution to WPPF & Welfare Funds		**4,303,836**	**3,133,926**	**2,296,499**	**1,603,458**
Contribution to WPPF & Welfare Funds		(215,810)	(151,915)	(119,718)	(78,529)
Profit Before Tax		**4,088,026**	**2,982,011**	**2,176,781**	**1,524,929**
Income Tax Expenses		**(956,155)**	**(755,712)**	**(520,456)**	**(382,971)**
Current Tax		(997,087)	(727,652)	(566,289)	(368,973)
Deferred Tax	16	40,932	(28,060)	45,833	(13,998)
Profit After Tax		**3,131,871**	**2,226,299**	**1,656,325**	**1,141,958**
Profit/(Loss) Attributable to:					
Owners of the Company		3,178,016	2,208,684	1,712,708	1,134,206
Non-controlling Interest		(46,145)	17,615	(56,383)	7,752
		3,131,871	**2,226,299**	**1,656,325**	**1,141,958**
Other Comprehensive Income-Unrealized Gain/(Loss)		9,887	7,503	1,880	5,606
Total Comprehensive Income		**3,141,758**	**2,233,802**	**1,658,205**	**1,147,564**
Total Comprehensive Income Attributable to:					
Owners of the Company		3,187,903	2,216,187	1,714,588	1,139,812
Non-controlling Interest		(46,145)	17,615	(56,383)	7,752
		3,141,758	**2,233,802**	**1,658,205**	**1,147,564**
Earnings Per Share (EPS)		**7.12**	**4.95**	**3.84**	**2.54**
Number of Shares	Nos.	446,112,089	446,112,089	446,112,089	446,112,089

Osman Kaiser Chowdhury Director	**A B Siddiqur Rahman** Director	**Nazmul Hassan** Managing Director	**Mohammad Ali Nawaz** Chief Financial Officer	**Mohammad Asad Ullah, FCS** Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Changes in Equity (Un-audited)
For the Period July - December 2021

As at December 31, 2021

Taka '000

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Equity attributable to the Owners of the Company	Non-Controlling Interests	Total Equity
Balance as on July 01, 2021	**4,461,121**	**5,269,475**	**1,689,637**	**294,951**	**1,121,825**	**13,767**	**24,179,783**	**37,030,559**	**334,307**	**37,364,866**
NCI at the date of acquisition-SBL	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**3,857,135**	**3,857,135**
Total Comprehensive Income:										
Profit/(Loss) for the Period	-	-	-	-	-	-	3,178,016	3,178,016	(46,145)	3,131,871
Other Comprehensive Income/(Loss)	-	-	-	-	-	9,887	-	9,887	-	9,887
Transactions with the Shareholders:										
Cash Dividend	-	-	-	-	-	-	(1,561,392)	(1,561,392)	(6,947)	(1,568,339)
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(3,179)	-	3,179	-	-	-
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	715	-	-	715	-	715
Balance as on December 31, 2021	**4,461,121**	**5,269,475**	**1,689,637**	**294,951**	**1,119,361**	**23,654**	**25,799,586**	**38,657,785**	**4,138,350**	**42,796,135**
Number of Shares								446,112,089		
Net Asset Value (NAV) Per Share							**Tk.**	**86.65**		

As at December 31, 2020

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Equity attributable to the Owners of the Company	Non-Controlling Interests	Total Equity
Balance as on July 01, 2020	4,055,564	5,269,475	1,689,637	294,951	1,125,768	926	20,058,800	32,495,121	302,329	32,797,450
Total Comprehensive Income:										
Profit/(Loss) for the Period	-	-	-	-	-	-	2,208,684	2,208,684	17,615	2,226,299
Other Comprehensive Income/(Loss)	-	-	-	-	-	7,503	-	7,503	-	7,503
Transactions with the Shareholders:										
Cash Dividend		-	-	-	-	-	(608,335)	(608,335)	(6,078)	(614,413)
Stock Dividend	405,556	-	-	-	-	-	(405,556)	-	-	-
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(3,590)	-	3,590	-	-	-
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	898	-	-	898	-	898
Balance as on December 31, 2020	**4,461,120**	**5,269,475**	**1,689,637**	**294,951**	**1,123,076**	**8,429**	**21,257,183**	**34,103,871**	**313,866**	**34,417,737**
Number of Shares								446,112,089		
Net Asset Value (NAV) Per Share							**Tk.**	**76.45**		

Osman Kaiser Chowdhury	**A B Siddiqur Rahman**	**Nazmul Hassan**	**Mohammad Ali Nawaz**	**Mohammad Asad Ullah, FCS**
Director	Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Cash Flows (Un-audited)
For the Period July - December 2021

Taka '000

	Notes	July - December 2021	July - December 2020
Cash Flows from Operating Activities :			
Receipts from Customers and Others		17,567,608	14,968,135
Payments to Suppliers and Employees		(12,809,303)	(11,819,166)
Cash Generated from Operations		**4,758,305**	**3,148,969**
Interest Paid		(433,470)	(502,855)
Interest Received		1,425	1,318
Income Tax Paid		(658,071)	(457,768)
Net Cash Generated from Operating Activities	**17**	**3,668,189**	**2,189,664**
Cash Flows from Investing Activities :			
Acquisition of Property, Plant and Equipment		(1,661,113)	(864,972)
Intangible Assets		(3,355)	(8,819)
Investment in Subsidiary		(4,766,636)	-
Disposal of Property, Plant and Equipment		12,402	21,171
Net Cash Used in Investing Activities		**(6,418,702)**	**(852,620)**
Cash Flows from Financing Activities :			
Net Increase /(Decrease) in Long Term Borrowings		3,622,081	(532,178)
Net Increase/(Decrease) in Short Term Borrowings		(596,880)	(1,038,577)
Dividend Paid		(71,505)	(6,701)
Net Cash (Used in) / from Financing Activities		**2,953,696**	**(1,577,456)**
Increase/(Decrease) in Cash and Cash Equivalents		**203,183**	**(240,412)**
Cash and Cash Equivalents at Beginning of Period*		973,965	635,017
Effect of Exchange Rate Changes on Cash and Cash Equivalents		3,553	-
Cash and Cash Equivalents at End of Period	**10**	**1,180,701**	**394,605**
Number of Shares		446,112,089	446,112,089
Net Operating Cash Flows Per Share		**8.22**	**4.91**

* Includes cash of Sanofi Bangladesh at the date of acquisition.

Osman Kaiser Chowdhury	**A B Siddiqur Rahman**	**Nazmul Hassan**	**Mohammad Ali Nawaz**	**Mohammad Asad Ullah, FCS**
Director	Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiaries
Selected Notes to the Financial Statements (Un-audited)
For the Period July - December 2021

Reporting Entity

1.1 About the Company

Beximco Pharmaceuticals Limited (BPL/ the Company) is a public limited Company incorporated in Bangladesh in 1976. It is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company was listed with Dhaka Stock Exchange in 1985 and Chittagong Stock Exchange on its debut in 1995. In 2005, BPL took over Beximco Infusions Ltd., a listed company engaged in manufacturing and marketing of intravenous fluids and got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). In 2018, BPL acquired 85.22% shares of Nuvista Pharma Limited – a non-listed pharmaceutical company in Bangladesh specializing in hormones and steroid drugs and took over control of its management. In 2021, Beximco Pharma acquired 54.6% stake in Sanofi Bangladesh Limited, the Bangladesh operation of global biopharmaceutical company Sanofi S.A. Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs in AIM of the London Stock Exchange.

The registered office of the Company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka. The manufacturing facilities of the Company are certified by leading global regulatory authorities including United States Food and Drug Administration (USFDA).

1.2 The Subsidiaries

Nuvista Pharma Limited (NPL)

Nuvista Pharma, formerly Organon (Bangladesh) Ltd., was a subsidiary of Netherlands based Organon International. The Company has been operating in Bangladesh since 1964, with a local manufacturing facility at Tongi, Dhaka. In the post-independent Bangladesh, it was incorporated as Organon (Bangladesh) Limited under Bangladesh Companies Act as a private limited company. In 2006 the foreign shareholding was sold out to Bangladeshi management and was renamed as Nuvista Pharma Limited (NPL). The Company through amendments to its memorandum of association in 2011 converted it into a public limited company. In 2018, Beximco Pharmaceuticals Limited acquired majority shareholdings in Nuvista Pharma and became the immediate and ultimate parent of the company.

Beximco Pharma API Limited (BPAL)

Beximco Pharma API Limited was formed as a private limited company in December 2017 with a paid up capital of Taka 20 million divided into 2 million shares of Taka 10 each, fully held by BPL excepting 10 shares. The Company intends to set up a facility at API Industrial Park to manufacture Active Pharmaceutical Ingredients (APIs) for domestic and international markets. The Company is still in the initial phase of establishment.

Sanofi Bangladesh Limited (SBL)

Beximco Pharmaceuticals Limited acquired 54.6% stake of SBL held by Sanofi Group represented through May & Baker Limited and Fisons Limited. The remaining 45.4% is held by Bangladesh Government through Bangaldesh Chemical Industries Corporation (20%) and Ministry of Industries (25.4%). Sanofi Bangladesh's state-of-the-art manufacturing facilities, including a PIC/S certifiable manufacturing facility for the leading antibiotic, cephalosporin, are spread over c25 acres of land, located at Tongi, Gazipur. The plant operated by SBL has manufacturing capabilities across several drug technologies, including tablets,capsules, topical, liquids, powder for suspension as well as sterile liquids and powders. The Corporate Headquarters is located at Segun Bagicha, Dhaka in a six storied building over a 26 katha land. Beximco Pharma took over the control of the company effective from 01 October 2021.

1.3 Nature of Business

BPL is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a wide range of therapeutic categories. It offers products in different dosage forms including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable, Large Volume Intravenous Fluids. Besides formulation products BPL also manufactures Active Pharmaceutical Ingredients (APIs) and renders contract manufacturing services to other companies. Products of the Company are sold in domestic and international markets.

NPL produces various pharmaceutical products including oral contraceptives, hormone, steroid, anti-histamine, anti-fibrinolytic, anti-infective, gastrointestinal, musculoskeletal, respiratory, vitamin & mineral supplement and women's health products which are sold in the domestic market.

SBL produces approximately 100 branded generic products and has a strong presence in cardiology, diabetes, oncology, dermatology and CNS. SBL also imports certain global brands of Sanofi including vaccines, insulins and chemotherapy drugs for sale in the Bangladesh market.

BPL and it's subsidiaries provide contract manufacturing services.

2. Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended June 30, 2021 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting. The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the Company's functional currency. All financial information presented has been rounded off to the nearest thousand Taka except where indicated otherwise.

3. Comparative Information

Beximco Pharma acquired majority stake in Sanofi Bangladesh Limited (SBL) through which SBL became a subsidiary of the Company with effect from October 1, 2021. SBL has been consolidated for the first time in this reproting period and as such comparative prior period does not include financials of SBL.

4. Significant Accounting Policies

4.1 Basis of Consolidation

The financial statements of the subsidiaries-Nuvista Pharma Limited, Sanofi Bangladesh Limited and Beximco Pharma API Limited, have been consolidated with those of Beximco Pharmaceuticals Limited in accordance with IFRS 10: Consolidated Financial Statements.

The Company acquired 85.22% shares of the issued paid up capital of Nuvista Pharma Limited. This ownership interest is adequate enough to establish control over NPL and thus BPL meets the conditions as stated in IFRS 10: Consolidated Financial Statements to consider NPL as a subsidiary.

The Company acquired 54.6% shares of the issued paid up capital of Sanofi Bangladesh Limited. This ownership interest is adequate enough to establish control over SBL and thus BPL meets the conditions as stated in IFRS 10: Consolidated Financial Statements to consider SBL as a subsidiary.

Beximco Pharma API Limited (BPAL) was formed with a paid up capital of Tk.20,000,000 divided into 2,000,000 shares of Tk.10 each, all of which excepting 10 shares are held by Beximco Pharmaceuticals Ltd (BPL). Beximco Pharma API Ltd thus meets the conditions stated in IFRS 10: Consolidated Financial Statements to consider it as a subsidiary.

4.2 Inter-Company Transactions

Assets, Liabilities, Equity, Income, Expenses and Cash Flows arising out of transactions between the Company and the subsidiary have been eliminated in full in the Consolidated Financial Statements.

4.3. Non-Controlling Interests (NCIs)

Non-Controlling Interests (NCIs) at the date of acquisition has been measured at fair value of the net assets of the acquired company in proportion to the shares of the entitled holders. Profit or Loss and Other Comprehensive Income subsequent to the acquisition has been allocated to the Owners of the Company and to the NCIs and also disclosed in the financial statements.

4.4. Valuation of Goodwill

Goodwill has been determined in accordance with IFRS 3: Business Combination. This represents the excess of the aggregate of Purchase Consideration and the acquisition-date fair value of NCI's share in the net assets over the acquisition-date fair value of the net assets of the subsidiary.

4.5 Investment in Associates

Investment in Associates has been accounted for using the Equity method as per IAS 28: Investment in Associates and Joint Ventures.

		Taka '000
	As at December 31, 2021	As at June 30, 2021

5. Property, Plant & Equipment - Carrying Value

Land	7,468,877	4,067,830
Building and Other Constructions	9,011,601	8,128,722
Plant and Machinery	18,224,375	16,847,214
Furniture and Fixtures	442,386	352,875
Transport and Vehicle	795,547	809,125
Office Equipment	1,021,492	653,815
	36,964,278	**30,859,581**
Less :Accumulated Depreciation	(13,470,019)	(11,155,642)
Net Book Value	**23,494,259**	**19,703,939**
Capital Work in Progress	18,361,713	16,507,437
Carrying Value	**41,855,972**	**36,211,376**

6. Goodwill

It includes:

Acquisition of 85.22% stake in Nuvista Pharma Limited	546,691	546,691
Acquisition of 54.6% stake in Sanofi Bangladesh Limited.*	127,880	-
	674,571	**546,691**

*Beximco Pharma completed the acquisition of 54.6% stake in Sanofi Bangladesh Limited (SBL) at a consideration of Taka 469.62 crore pending final closing adjustments, if any. The transfer of ownership was completed by end of business day of September 30, 2021 and SBL effectively became a subsidiary of Beximco Pharma from October 1, 2021. SBL therefore, has been consolidated for the first time in the current reporting period.

The Company engaged PricewaterhouseCoopers Bangladesh Pvt. Ltd. to determine the Fair Value for the tangible assets and identified intangible assets as per criteria set out in International Financial Reporting Standards (IFRS 3: Business Combination). Management has considered the report of the said independent firm in allocating the total consideration paid for the acquisition among various classes of acquired assets and goodwill in compliance of the requirement of IFRS 3. Based on provisional purchase consideration goodwill has been determined as per the following manner:

Purchase Consideration*	4,766,636
Non-Controlling Interest at the date of acquisition	3,857,135
	8,623,771
Less: Acquisition date Fair Value of Identifiable Net Assets	(8,495,891)
	127,880

*Purchase consideration includes share transfer fee of Taka 70,443,188 paid to the Registrar of Joint Stock Companies and Firms.

Goodwill is determined based on provisional purchase consideration which is subject to adjustments upon finalization of closing date accounts. Goodwill may increase/decrease based on final purchase consideration in line with measurement criteria as stipulated in clause 45 of IFRS-3: Business Combination.

		Taka '000
	As at December 31, 2021	As at June 30, 2021
7. Other Investments		
Bangladesh Export Import Co. Ltd.	24,910	15,023
Central Depository Bangladesh Ltd. (CDBL)	1,569	1,569
	26,479	**16,592**
8. Inventories		
Finished Goods	2,354,132	1,299,682
Raw and Packing Materials (Including Work in Process, Laboratory Chemicals, R & D Materials and Material in Transit)	6,914,494	5,763,417
Physician Sample	82,830	79,764
	9,351,456	**7,142,863**
9. Loans, Advances and Deposits		
Clearing & Forwarding	135,145	249,539
VAT	427,545	488,144
Security Deposit and Earnest Money	175,529	167,929
Lease Deposit	2,133	2,650
Advance for Expenses including Capital Expenditure	555,076	423,937
Bank Guarantee Margin	18,590	20,831
Salary Advance/Loan	158,976	186,445
Motor Cycle	160,668	148,885
Raw & Packing Material	470,683	460,857
Overseas Liaison Office	65,926	58,208
Others	186,918	209,523
	2,357,189	**2,416,948**
10. Cash and Cash Equivalents		
(a) Cash in Hand (Including Imprest Cash)	339,041	164,563
(b) Cash at Bank:		
Current and FC Account	740,953	470,766
FDR & SND Account	100,707	40,138
	1,180,701	**675,467**
11. Long Term Borrowings		
A. Net of Current Maturity		
Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	905,076	972,696
Agrani Bank Limited	2,975,387	-
Lease Liability	349,343	234,021
	4,229,806	**1,206,717**
B. Current Maturity		
Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	1,294,319	1,287,430
Agrani Bank Limited	623,538	-
Lease Liability	142,809	113,976
	2,060,666	**1,401,406**

C. The Company availed a Term Loan of Taka 3,750 million from Agrani Bank Limited, Principal Branch Dhaka to partly finance the acquisition of Sanofi Bangladesh Limited.

D. Exchange fluctuation gain of Tk. 10,251K has been incurred on conversion of outstanding foreign currency loan to functional currency at the exchange rate prevailing on the date of Statement of Financial Position.

	Taka '000	
	For the Period July - December 2021	**For the Period July - December 2020**
12. Cost of Goods Sold		
Work-in-Process (Opening)	355,080	294,258
Materials Consumed	7,853,637	6,038,741
Factory Overhead Consumed	1,955,479	1,858,471
Total Manufacturing Cost	**10,164,196**	**8,191,470**
Work-in-Process (Closing)	(672,339)	(207,829)
Cost of Goods Manufactured	**9,491,857**	**7,983,641**
Finished Goods (Opening)	1,858,055	1,128,728
Finished Goods available	**11,349,912**	**9,112,369**
Cost of Physician Sample transferred to Sample Stock	(196,523)	(163,729)
Finished Goods (Closing)	(2,354,132)	(1,380,041)
	8,799,257	**7,568,599**
13. Administrative Expenses		
Salary & Allowances	327,086	239,763
Repairs & Maintenance	32,240	27,253
Travelling & Conveyance	15,025	13,032
Company Secretarial, Regulatory Fee and AGM Expense	17,207	12,149
Depreciation	26,700	16,595
Security Expenses	10,358	6,226
Business Acquisition Cost	7,142	-
Other Expenses	138,081	88,614
	573,839	**403,632**
14. Selling, Marketing and Distribution Expenses		
Salary & Allowances	1,451,489	1,144,980
Travelling & Conveyance	330,232	301,851
Market Research & New Products	28,401	24,639
Sample Expenses	252,379	213,749
Literature and News Letter	153,200	121,743
Events, Programs & Campaigns	158,653	96,329
Brand Development	66,831	61,188
Sales Promotion Expenses	90,534	63,250
Distribution Commission	257,515	215,252
Delivery Expense	195,541	200,938
Depreciation and Amortization	117,182	78,055
Export Insurance, Freight and C & F Expenses	103,577	71,291
Security Expenses	9,524	9,124
Bad Debts	1,425	1,525
Other Expenses	445,104	357,176
	3,661,587	**2,961,090**

Taka '000

	For the Period July - December 2021	For the Period July - December 2020
15. Other Income		
Interest Income	1,425	1,318
Cash Incentive on Export	100,899	145,235
Royalty	50,071	21,248
Exchange Rate Fluctuation Gain/(loss)	13,890	452
Profit/(Loss) on Sale of Fixed Assets	2,700	-
Sale of Product Dossier	-	989
Vaccine Distribution Fee	619,259	-
Miscellaneous Income	13,728	671
	801,972	**169,913**
16. Deferred Tax		
16 A. Deferred Tax Liability & Expense/(Income)-BPL & NPL		
Deferred Tax is arrived at as follows :		
Property, Plant & Equipment -Difference in book value & Tax base	9,966,389	9,830,702
Deferred Liability (Gratuity)	(1,360,953)	(1,248,669)
Allowance for Bad Debts	(11,479)	(8,079)
Temporary Difference	**8,593,957**	**8,573,954**
Tax Rate	-	-
Deferred Tax Liability at end of the period	1,983,484	2,194,846
Deferred Tax Liability at beginning of the period	1,989,566	2,167,684
Change in Deferred Tax Liability	**(6,082)**	**27,162**
Deferred Tax on Revaluation Surplus	715	898
Deferred Tax Expense /(Income)	**(5,367)**	**28,060**
16 B. Deferred Tax Asset & Expense/(Income)-SBL		
Deferred Tax is arrived at as follows :		
Property, Plant & Equipment (Difference in book value & Tax base)	265,025	-
Deferred Liability (Gratuity & Pension)	(123,310)	-
Allowance for Bad Debts, Inventories & Others	(232,834)	-
Tax on Loss carry forward	(160,558)	-
Temporary Difference	**(251,677)**	**-**
Tax Rate	30%	-
Deferred Tax Asset	(75,504)	-
Deferred tax on actuarial valuation (Equity Impact)	2,864	-
Deferred Tax Asset at end of the period	(72,640)	-
Deferred Tax Asset at beginning of the period	(37,075)	-
Change in Deferred Tax Asset	**(35,565)**	**-**
Deferred Tax on Revaluation Surplus	-	-
Deferred Tax Expense/(Income)-SBL	**(35,565)**	**-**
16 C. Total Deferred Tax Expense/(Income)		
Deferred Tax Expense/(Income)-SBL	(35,565)	-
Deferred Tax Expense/(Income)-BPL & NPL	(5,367)	28,060
	(40,932)	**28,060**

		Taka '000
	For the Period July - December 2021	For the Period July - December 2020
17. Reconciliation of Net Profit with Cash Flows from Operating Activities		
Profit After Tax	**3,131,871**	**2,226,299**
Adjustment to reconcile net profit to Net Cash Generated from Operating Activities :		
Non-cash / Non-operating items:	**953,385**	**766,460**
Depreciation	544,071	484,645
Amortization	82,232	45,553
Gratuity & WPPF	384,518	204,432
Deferred Tax	(40,932)	28,060
Exchange Rate Fluctuation Gain on Foreign Currency Bank Loan	(10,251)	3,775
Gain on Sale of Fixed Assets	(2,700)	(5)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(3,553)	-
Changes in Working Capital	**(417,067)**	**(803,095)**
Inventories	(1,454,164)	(824,933)
Spares & Supplies	(86,756)	(82,852)
Accounts Receivable	(125,314)	396,248
Loans, Advances & Deposits	360,319	(493,724)
Advance Income Tax	(5,671)	-
Creditors and Other Payables	431,871	(175,407)
Accrued Expenses	117,961	107,689
Income Tax Payable	344,687	269,884
Net Cash Generated from Operating Activities	**3,668,189**	**2,189,664**

18. Related Party Transaction

Name of Related Parties	Nature of Transactions	Value of Transaction	Balance at period end
I & I Services Limited	Local Delivery	16,213,366	1,098,277
	Distribution Commission	257,515	

19. Significant Deviations

Sanofi Bangladesh Limited has been consolidated for the first time in this reporting period and as such comparative prior period unaudited figures (July-December 2020) as reported in the Consolidated Statement of Financial Position, Consolidated Statement of Profit or Loss and Other Comprehensive Income, Consolidated Statement of Changes in Equity and Consolidated Statement of Cash Flows do not include financials of Sanofi Bangladesh Limited.

The Company achieved over 17% growth in consolidated sales as compared to prior period. Moreover, other income also increased predominently due to income from vaccine distribution fee which was not there in the comparative prior period. These have contributed towards increase in consolidated earning per share. Consolidated operating cash flow per share also increased due to higher revenue and improved net working capital.

Osman Kaiser Chowdhury Director	**A B Siddiqur Rahman** Director	**Nazmul Hassan** Managing Director	**Mohammad Ali Nawaz** Chief Financial Officer	**Mohammad Asad Ullah, FCS** Executive Director & Company Secretary

Beximco Pharmaceuticals Limited

Financial Statements (Un-audited)

For the Period July - December 2021

Beximco Pharmaceuticals Limited
Statement of Financial Position (Un-audited)
As at December 31, 2021

Taka '000

	Notes	December 31, 2021	June 30, 2021
ASSETS			
Non-Current Assets		**43,995,559**	**37,713,989**
Property, Plant and Equipment- Carrying Value	3	35,922,933	34,501,205
Right-of-use Assets		433,415	319,885
Intangible Assets		671,584	701,795
Investment in Subsidiaries	4a	6,911,822	2,145,186
Investment In Associates		29,326	29,326
Other Investments	4b	26,479	16,592
Current Assets		**14,383,932**	**13,150,677**
Inventories	5	8,036,113	6,693,894
Spares & Supplies		696,309	622,433
Accounts Receivable		3,079,214	2,831,869
Loans, Advances and Deposits	6	1,776,908	2,354,576
Cash and Cash Equivalents	7	795,388	647,905
TOTAL ASSETS		**58,379,491**	**50,864,666**
EQUITY AND LIABILITIES			
Shareholders' Equity		**38,340,643**	**36,707,592**
Issued Share Capital		4,461,121	4,461,121
Share Premium		5,269,475	5,269,475
Excess of Issue Price over Face Value of GDRs		1,689,637	1,689,637
Capital Reserve on Merger		294,951	294,951
Revaluation Surplus		1,119,361	1,121,825
Unrealized Gain/(Loss)		23,654	13,767
Retained Earnings		25,482,444	23,856,816
Non-Current Liabilities		**8,573,014**	**5,265,836**
Long Term Borrowings-Net of Current Maturity	8 A	4,175,577	1,206,717
Liability for Gratuity and WPPF & Welfare Funds		2,527,384	2,187,145
Deferred Tax Liability	14	1,870,053	1,871,974
Current Liabilities and Provisions		**11,465,834**	**8,891,238**
Short Term Borrowings		4,437,907	4,857,106
Long Term Borrowings-Current Maturity	8 B	2,047,570	1,401,406
Creditors and Other Payables		2,282,657	1,814,013
Accrued Expenses		562,594	480,502
Dividend Payable / Unclaimed Dividend	9	1,614,548	117,770
Income Tax Payable		520,558	220,441
TOTAL EQUITY AND LIABILITIES		**58,379,491**	**50,864,666**

Osman Kaiser Chowdhury	**A B Siddiqur Rahman**	**Nazmul Hassan**	**Mohammad Ali Nawaz**	**Mohammad Asad Ullah, FCS**
Director	Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period July - December 2021

Taka '000

	Notes	July - December 2021	July - December 2020	October - December 2021	October - December 2020
Net Sales Revenue		**15,259,624**	**13,196,162**	**7,454,524**	**6,853,828**
Cost of Goods Sold	10	(7,919,074)	(6,995,893)	(3,838,224)	(3,636,178)
Gross Profit		**7,340,550**	**6,200,269**	**3,616,300**	**3,217,650**
Operating Expenses		**(3,536,285)**	**(3,018,689)**	**(1,755,935)**	**(1,568,975)**
Administrative Expenses	11	(449,451)	(352,020)	(231,586)	(179,788)
Selling, Marketing and Distribution Expenses	12	(3,086,834)	(2,666,669)	(1,524,349)	(1,389,187)
Profit from Operations		**3,804,265**	**3,181,580**	**1,860,365**	**1,648,675**
Other Income	13	918,517	282,560	802,928	151,738
Finance Cost		(423,842)	(492,702)	(260,973)	(265,976)
Profit Before Contribution to WPPF & Welfare Funds		**4,298,940**	**2,971,438**	**2,402,320**	**1,534,437**
Contribution to WPPF & Welfare Funds		(204,711)	(141,497)	(114,396)	(73,068)
Profit Before Tax		**4,094,229**	**2,829,941**	**2,287,924**	**1,461,369**
Income Tax Expenses		**(910,388)**	**(687,637)**	**(510,397)**	**(347,295)**
Current Tax		(911,594)	(654,694)	(517,783)	(330,667)
Deferred Tax	14	1,206	(32,943)	7,386	(16,628)
Profit after Tax		**3,183,841**	**2,142,304**	**1,777,527**	**1,114,074**
Other Comprehensive Income/(Loss)		9,887	7,503	1,880	5,606
Total Comprehensive Income		**3,193,728**	**2,149,807**	**1,779,407**	**1,119,680**
Earnings Per Share (EPS)		7.14	4.80	3.98	2.50
Number of Shares		**446,112,089**	**446,112,089**	**446,112,089**	**446,112,089**

Osman Kaiser Chowdhury Director	**A B Siddiqur Rahman** Director	**Nazmul Hassan** Managing Director	**Mohammad Ali Nawaz** Chief Financial Officer	**Mohammad Asad Ullah, FCS** Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Statement of Changes in Equity (Un-audited)
For the Period July - December 2021

As at December 31, 2021

Taka' 000

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Total
Balance as on July 01, 2021	**4,461,121**	**5,269,475**	**1,689,637**	**294,951**	**1,121,825**	**13,767**	**23,856,816**	**36,707,592**
Total Comprehensive Income								
Profit for the Period	-	-	-	-	-	-	3,183,841	3,183,841
Other Comprehensive Income/(Loss)	-	-	-	-	-	9,887	-	9,887
Transactions with the Shareholders:								
Cash Dividend	-	-	-	-	-		(1,561,392)	(1,561,392)
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(3,179)	-	3,179	-
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	715	-	-	715
Balance as on December 31, 2021	**4,461,121**	**5,269,475**	**1,689,637**	**294,951**	**1,119,361**	**23,654**	**25,482,444**	**38,340,643**
Number of Shares								446,112,089
Net Asset Value (NAV) Per Share							Tk.	**85.94**

As at December 31, 2020

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Total
Balance as on July 01, 2020	**4,055,564**	**5,269,475**	**1,689,637**	**294,951**	**1,125,768**	**926**	**19,920,038**	**32,356,359**
Total Comprehensive Income :								
Profit for the Period	-	-	-	-	-	-	2,142,304	2,142,304
Other Comprehensive Income / (Loss)	-	-	-	-	-	7,503	-	7,503
Transaction with the Shareholders :								
Cash Dividend	-	-	-	-	-	-	(608,335)	(608,335)
Stock Dividend	405,556	-	-	-	-	-	(405,556)	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(3,590)	-	3,590	-
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	898	-	-	898
Balance as on December 31, 2020	**4,461,120**	**5,269,475**	**1,689,637**	**294,951**	**1,123,076**	**8,429**	**21,052,041**	**33,898,729**
Number of Shares								446,112,089
Net Asset Value (NAV) Per Share							Tk.	75.99

Osman Kaiser Chowdhury	**A B Siddiqur Rahman**	**Nazmul Hassan**	**Mohammad Ali Nawaz**	**Mohammad Asad Ullah, FCS**
Director	Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Statement of Cash Flows (Un-audited)
For the Period July - December 2021

Taka '000

	Notes	July - December 2021	July - December 2020
Cash Flows from Operating Activities :			
Receipts from Customers and Others		15,873,820	13,826,936
Payments to Suppliers and Employees		(11,476,581)	(10,939,309)
Cash Generated from Operations		**4,397,239**	**2,887,627**
Interest Paid		(423,842)	(492,702)
Interest Received		594	1,318
Income Tax Paid		(611,477)	(413,417)
Net Cash Generated from Operating Activities	15	**3,362,514**	**1,982,826**
Cash Flows from Investing Activities :			
Acquisition of Property, Plant and Equipment		(1,642,324)	(841,092)
Intangible Assets		(3,355)	(8,819)
Investment in Subsidiary		(4,766,636)	-
Disposal of Property, Plant and Equipment		12,215	21,166
Dividend Received		40,054	35,047
Net Cash Used in Investing Activities		**(6,360,046)**	**(793,698)**
Cash Flows from Financing Activities :			
Net Increase /(Decrease) in Long Term Borrowings		3,625,275	(489,697)
Net Increase/(Decrease) in Short Term Borrowings		(419,199)	(952,438)
Dividend Paid		(64,614)	(680)
Net Cash (Used in) / from Financing Activities		**3,141,462**	**(1,442,815)**
Increase / (Decrease) in Cash and Cash Equivalents		**143,930**	**(253,687)**
Cash and Cash Equivalents at Beginning of Period		647,905	615,945
Effect of Exchange Rate Changes on Cash and Cash Equivalents		3,553	-
Cash and Cash Equivalents at End of Period		**795,388**	**362,258**
Number of Shares		446,112,089	446,112,089
Net Operating Cash Flows Per Share		**7.54**	**4.44**

Osman Kaiser Chowdhury	**A B Siddiqur Rahman**	**Nazmul Hassan**	**Mohammad Ali Nawaz**	**Mohammad Asad Ullah, FCS**
Director	Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Selected Notes to the Financial Statements (Un-audited)
For the Period July - December 2021

1. Reporting Entity

1.1 About the Company

Beximco Pharmaceuticals Limited (BPL/ the Company) is a public limited company incorporated in Bangladesh in 1976. It is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company was listed with Dhaka Stock Exchange in 1985 and Chittagong Stock Exchange on its debut in 1995. In 2005, BPL took over Beximco Infusions Ltd., a listed company engaged in manufacturing and marketing of intravenous fluids and got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). BPL holds 85.22% shares of Nuvista Pharma Limited - a non-listed pharmaceutical company in Bangladesh specializing in hormones and steroid drugs. In 2021, Beximco Pharma acquired 54.6% stake in Sanofi Bangladesh Limited, the Bangladesh operation of global biopharmaceutical company Sanofi S.A. Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs in AIM of the London Stock Exchange.

The registered office of the Company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka. The manufacturing facilities of the Company are certified by leading global regulatory authorities including United States Food and Drug Administration (USFDA).

1.2 Nature of Business

The Company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a wide range of therapeutic categories. It offers products in different dosage forms including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable, Large Volume Intravenous Fluids. BPL also manufactures Active Pharmaceutical Ingredients (APIs) and renders contract manufacturing services to other companies. Products of the Company are sold in domestic and international markets.

2. Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended June 30, 2021 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting. The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the Company's functional currency. All financial information presented has been rounded off to the nearest thousand Taka except where indicated otherwise.

		Taka '000	
		As at December 31, 2021	As at June 30, 2021
3.	**Property, Plant & Equipment - Carrying Value**		
	Land	3,343,741	3,343,741
	Building and Other Constructions	7,806,095	7,801,664
	Plant and Machinery	15,547,425	15,543,388
	Furniture and Fixtures	312,632	300,332
	Transport and Vehicle	655,336	664,903
	Office Equipment	633,990	623,299
		28,299,219	**28,277,327**
	Less : Accumulated Depreciation	(10,648,598)	(10,250,391)
	Net Book Value	**17,650,621**	**18,026,936**
	Capital Work in Progress	18,272,312	16,474,269
	Carrying Value	**35,922,933**	**34,501,205**
4a.	**Investment in Subsidiaries**		
	It consists of:		
	Nuvista Pharma Limited (85.22% stake)	2,125,186	2,125,186
	Sanofi Bangladesh Limited (54.6% stake)*	4,766,636	-
	Beximco Pharma API Limited (99.99% stake)	20,000	20,000
		6,911,822	**2,145,186**
	* This is a provisional consideration and is subject to adjustments, if any, depending on finalization of the closing accounts on acquisition date.		
4b.	**Other Investment**		
	Bangladesh Export Import Co. Ltd.	24,910	15,023
	Central Depository Bangladesh Ltd. (CDBL)	1,569	1,569
		26,479	**16,592**
5.	**Inventories**		
	Finished Goods	1,673,718	1,188,527
	Raw and Packing Materials (Including Work in Process, Laboratory Chemicals, R & D Materials and Material in Transit)	6,279,565	5,425,603
	Physician Sample	82,830	79,764
		8,036,113	**6,693,894**
6.	**Loans, Advances and Deposits**		
	Clearing & Forwarding	135,145	249,539
	VAT	404,182	463,448
	Security Deposit and Earnest Money	111,646	164,446
	Lease Deposit	2,133	2,650
	Advance for Expenses including Capital Expenditure	197,277	422,348
	Bank Guarantee Margin	18,590	20,831
	Advance against Salary	81,162	173,757
	Motor Cycle	149,014	148,885
	Raw & Packing Material	470,683	460,857
	Overseas Liaison Office	65,926	58,208
	Others	141,150	189,607
		1,776,908	**2,354,576**

		Taka '000
	As at December 31, 2021	As at June 30, 2021
7. Cash and Cash Equivalents		
(a) Cash in Hand (Including Imprest Cash)	338,845	164,392
(b) Cash at Bank:		
Current and FC Account	456,543	443,375
FDR Account	-	40,138
	795,388	**647,905**
8. Long Term Borrowings		
A. Net of Current Maturity		
Project Loan - ODDO BHF Aktiengesellshaft, Frankfurt, Germany	905,076	972,696
Agrani Bank Limited	2,975,387	-
Leases Liability	295,114	234,021
	4,175,577	**1,206,717**
B. Current Maturity		
Project Loan - ODDO BHF Aktiengesellshaft, Frankfurt, Germany	1,294,319	1,287,430
Agrani Bank Limited	623,538	-
Leases Liability	129,713	113,976
	2,047,570	**1,401,406**

C. The Company availed a Term Loan of Taka 3,750 million from Agrani Bank Limited, Principal Branch Dhaka to partly finance the acquisition of Sanofi Bangladesh Limited.

D. Exchange fluctuation gain of Tk. 10,251K has been incurred on conversion of outstanding foreign currency loan to functional currency at the exchange rate prevailing on the date of Statement of Financial Position.

9. Dividend Payable / Unclaimed Dividend

The cash dividend declared for the year 2020-21 were approved by the shareholders in the Annual General Meeting held on December 23, 2021. The Dividend Payable/Unclaimed dividend as on December 31, 2021 consists of Tk. 1,561,392K payable for the year 2020-21 which has been paid subsequent to the reporting period. The remaining balance Tk. 53,156K relates to dividend for prior years unclaimed to date.

Additionally, dividend amounting Tk. 64,297K was paid to Capital Market Stabilization Fund (CMSF) in compliance to BSEC directive no. BSEC/CMRRCD/2021-386/03 dated January 14, 2021

		Taka '000
	For the Period July - December 2021	For the Period July - December 2020
10. Cost of Goods Sold		
Work-in-Process (Opening)	282,756	249,839
Materials Consumed	7,274,070	5,728,993
Factory Overhead Consumed	1,603,841	1,607,922
Total Manufacturing Cost	**9,160,667**	**7,586,754**
Work-in-Process (Closing)	(565,543)	(158,411)
Cost of Goods Manufactured	**8,595,124**	**7,428,343**
Finished Goods (Opening)	1,188,527	972,564
Finished Goods available	**9,783,651**	**8,400,907**
Cost of Physician Sample transferred to Sample Stock	(190,859)	(158,749)
Finished Goods (Closing)	(1,673,718)	(1,246,265)
	7,919,074	**6,995,893**
11. Administrative Expenses		
Salary & Allowances	257,462	207,924
Repairs & Maintenance	27,856	24,762
Travelling & Conveyance	10,724	12,385
Company Secretarial, Regulatory Fee and AGM Expense	16,839	11,814
Depreciation	16,081	15,135
Security Expenses	8,563	6,226
Business Acquisition Cost	7,142	-
Other Expenses	104,784	73,774
	449,451	**352,020**
12. Selling, Marketing and Distribution Expenses		
Salary & Allowances	1,151,438	990,840
Travelling & Conveyance	274,618	261,469
Market Research & New Products	27,880	24,639
Sample Expenses	243,546	206,576
Literature and News Letter	135,989	108,747
Events, Programs & Campaign	139,793	91,346
Brand Development	62,200	57,532
Sales Promotion Expenses	72,007	55,339
Distribution Commission	257,515	215,252
Delivery Expense	195,541	200,938
Depreciation and Amortization	61,133	56,399
Export Insurance, Freight and C & F Expenses	102,911	71,291
Security Expenses	9,524	9,124
Bad Debts	1,425	1,525
Other Expenses	351,314	315,652
	3,086,834	**2,666,669**

		Taka '000
	For the Period July - December 2021	For the Period July - December 2020
13. Other Income		
Interest Income	594	1,318
Distribution Commission	73,189	65,919
Cash Incentive on Export	100,899	145,235
Dividend Income	40,054	35,047
Royalty	68,109	33,600
Exchange Rate Fluctuation Gain/(loss)	13,890	452
Sale of Product Dossier	-	989
Vaccine Distribution Fee	619,259	-
Profit/(Loss) on Sale of Fixed Assets	2,523	-
	918,517	**282,560**
14. Deferred Tax		
Deferred Tax is arrived at as follows :		
Property, Plant & Equipment -Difference in book value & Tax base	9,524,113	9,385,701
Deferred Liability (Gratuity)	(1,203,172)	(1,107,872)
Allowance for Bad Debts	(9,594)	(6,669)
Temporary Difference	**8,311,347**	**8,271,160**
Tax Rate	22.5%	25%
Deferred Tax Liability at end of the period	1,870,053	2,067,790
Deferred Tax Liability at beginning of the period	1,871,974	2,035,745
Change in Deferred Tax Liability	**(1,921)**	**32,045**
Deferred Tax on Revaluation Surplus	715	898
Deferred Tax	**(1,206)**	**32,943**
15. Reconciliation of Net Profit with Cash Flows from Operating Activities		
Profit after Tax	**3,183,841**	**2,142,304**
Adjustment to reconcile net profit to Net Cash Generated from Operating Activities :		
Non-cash / Non-operating Items:	**775,676**	**627,293**
Depreciation	459,458	432,424
Amortization	33,566	30,453
Gratuity & WPPF	340,239	162,745
Deferred Tax	(1,206)	32,943
Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan	(10,251)	3,775
Dividend Income	(40,054)	(35,047)
Loss /(Gain)on Sale of Fixed Assets	(2,523)	-
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(3,553)	-
Changes in Working Capital	**(597,003)**	**(786,771)**
Inventories	(1,342,219)	(785,783)
Spares & Supplies	(73,876)	(79,726)
Accounts Receivable	(247,345)	380,806
Loans, Advances & Deposits	449,591	(473,420)
Creditors and Other Payables	234,637	(190,337)
Accrued Expenses	82,092	120,412
Income Tax Payable	300,117	241,277
Net Cash Generated from Operating Activities	**3,362,514**	**1,982,826**

16. Related Party Transactions

Name of Related Parties	Nature of Transactions	Value of Transaction	Balance at period end	Balance Type
a. I & I Services Limited	Local Delivery Distribution Commission	16,213,366 257,515	1,098,277	Dr.
b. Nuvista Pharma Limited	Toll Manufacturing Cost of Services Royalty Dividend Paid Distribution Commission	15,795 27,629 18,038 40,054 73,189	3,057 4,145 3,504 - 12,880	Cr. Dr. Dr. Dr.
c. Sanofi Bangladesh Limited	Toll Manufacturing Cost of Goods Purchase	80,891 15,245	32,546 5,823	Cr. Dr.
d. Beximco Pharma API Limited	Short Term Advance	-	680	Dr.

Osman Kaiser Chowdhury
Director

A B Siddiqur Rahman
Director

Nazmul Hassan
Managing Director

Mohammad Ali Nawaz
Chief Financial Officer

Mohammad Asad Ullah, FCS
Executive Director & Company Secretary